Home › Funds › EcoR1 Capital, LLC › BBOT
EcoR1 Capital, LLC position in BBOT
BRIDGEBIO ONCOLOGY THERAPEUT · Health Care
EcoR1 Capital, LLC reported holding 889,607 shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) in its Q3 2026 13F filing — a position valued at US$3.6M, representing 0.17% of its reported portfolio and ranking #29 among its reported holdings. EcoR1 Capital, LLC has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How EcoR1 Capital, LLC's BBOT position evolved
EcoR1 Capital, LLC first disclosed a stake in BBOT in Q3 2025 at 2,823,126 shares (US$32.7M). The position peaked in Q4 2025 at 2,823,126 shares, worth US$35.3M. Across 5 filings, EcoR1 Capital, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 889,607 shares valued at US$3.6M — a reduction of -1,933,519 shares quarter over quarter.. Notable position changes include a 68% trim in Q3 2026 (shares fell 48% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 2.82M | $32.69M | New |
| Q4 2025 | 2.82M | $35.35M | Hold |
| Q1 2026 | 2.82M | $25.27M | Hold |
| Q2 2026 | 2.82M | $21.51M | Hold |
| Q3 2026 | 889.61K | $3.65M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBOT and 13F data
BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) is a Health Care company. 88 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Enavate Sciences GP, LLC (US$20.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Cormorant Asset Management, LP 17.88M sh · $136.23M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.89M sh · $37.23M · Q2 2026
- Enavate Sciences GP, LLC 2.63M sh · $20.02M · Q2 2026
- Novo Holdings A/S 2.25M sh · $17.14M · Q2 2026
- Omega Fund Management, LLC 3.29M sh · $13.49M · Q3 2026
- Alphabet Inc. 2.82M sh · $11.57M · Q3 2026
- REGENTS OF THE UNIVERSITY OF CALIFORNIA 2.51M sh · $10.29M · Q3 2026
- Opaleye Management Inc. 700.00K sh · $5.33M · Q2 2026
- Aisling Capital Management LP 1.02M sh · $4.14M · Q3 2026
- Catalio Capital Management, LP 318.41K sh · $2.43M · Q2 2026
- Casdin Capital 282.31K sh · $2.15M · Q2 2026
- Avidity Partners Management LP 43.85K sh · $334.16K · Q2 2026
More on EcoR1 Capital, LLC
FAQ
How long has EcoR1 Capital, LLC held BBOT?
EcoR1 Capital, LLC has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is EcoR1 Capital, LLC's current position in BBOT?
As of Q3 2026, EcoR1 Capital, LLC holds 889.61K shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), valued at $3.65M, representing 0.17% of its reported portfolio and ranking #29.
Has EcoR1 Capital, LLC been buying or selling BBOT?
In the latest 13F filing (Q3 2026), EcoR1 Capital, LLC reduced its position in BBOT. The position peaked in Q4 2025 at 2.82M shares.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Enavate Sciences GP, LLC, among 88 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.